Skip to main content
LFCR
NASDAQ Life Sciences

Wynnefield Locks Up 14.3% Stake Behind Webster Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.52
Mkt Cap
$249.452M
52W Low
$3.625
52W High
$8.98
52W Position info
80% above low
Off High info
27% below high
Rel. Volume info
3.2× avg
Market data snapshot near publication time

LFCR sits 80% above its 52-week low of $3.625 on elevated volume (3.2× avg).

Summary

Wynnefield Capital, Lifecore's largest activist holder at 14.3%, signed a voting agreement backing the Webster Equity Partners acquisition. The filing also confirms Wynnefield's full Series A Preferred redemption demand, payable December 28, 2026.


Key Events · Ownership and Investor Activity · LFCR

  • Wynnefield Signs Voting Agreement

    Wynnefield Capital entities, holding 5,512,211 shares (14.3%), agreed to vote all Covered Shares in favor of the Webster Equity Partners merger at $6.28 per share plus CVRs.

  • Transfer Restrictions and Appraisal Waiver

    The agreement restricts transfers of Covered Shares until the merger closes and irrevocably waives appraisal rights, locking in Wynnefield's support.

  • Series A Redemption Demand Confirmed

    Wynnefield delivered redemption notices for all Series A Preferred Stock on June 30, 2026, with payment due December 28, 2026 — a $52.1 million obligation previously disclosed as exceeding Lifecore's liquidity.

  • Ownership Details

    Wynnefield's 14.3% stake includes 644,395 shares issuable upon conversion of Series A Preferred Stock, based on 38,497,455 shares outstanding.


Analysis · LFCR · Life Sciences

Wynnefield Capital, holding 14.3% of Lifecore, signed a voting and support agreement backing the Webster Equity Partners acquisition at $6.28 per share plus CVRs. The agreement locks up 5.5 million shares, waives appraisal rights, and restricts transfers until the merger closes. Wynnefield also delivered redemption notices for all its Series A Preferred Stock on June 30, 2026, with payment due December 28, 2026 — a $52.1 million obligation that exceeds Lifecore's current liquidity and was previously flagged as a going-concern risk. This filing confirms the activist bloc is aligned with the deal, removing a key obstacle to closing.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LFCR was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.5M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LFCR - Latest Insights

LFCR
Nov 04, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.38
Real-time Price: $6.42 info
Change: +$0.0396 (+0.62%) info
Market Cap: $243.356M info
LFCR
Oct 30, 2026, 5:26 PM EDT
Filing Type: PREM14A
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $6.42 info
Change: +$0.020 (+0.31%) info
Market Cap: $243.356M info
LFCR
Sep 28, 2026, 5:41 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.62
Real-time Price: $6.42 info
Change: -$0.200 (-3%) info
Market Cap: $243.356M info
LFCR
Sep 28, 2026, 8:56 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $4.30
Real-time Price: $6.42 info
Change: +$2.12 (+49%) info
Market Cap: $243.356M info
LFCR
Sep 28, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.30
Real-time Price: $6.42 info
Change: +$2.12 (+49%) info
Market Cap: $243.356M info